Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Portfolio
  • Forum
  • Q&A
  • About Us
    • Our Coverage
    • Team
Analyst Comment

Remedy Q1 on Monday: Our forecast sees AW2 royalties only starting to show in the figures in H2

By Atte RiikolaAnalyst
Remedy Entertainment

Translation: Original comment published in Finnish on 4/23/2024 at 1:18 am EEST.

Remedy Q124pre

Remedy will report its Q1 results on Monday at 9.00 am EEST. We will review the report afresh in Remedy earnings live starting at 8.55 am (in Finnish). We still expect a very weak quarter in terms of numbers before AW2 starts to generate royalties in H2. Any further information on the sales development of the game (over 1.3 million copies sold at the beginning of February) will be of interest in the report. In addition, the decision on whether to choose a publishing partner or to self-publish Condor and Control 2 is one of the key issues concerning the company in the short term, but the report is unlikely to provide any further material information on the ongoing negotiations. This is an important long-term strategic decision that will shape the company's direction for the next decade. Given the potential of the Control Games brand, we believe that the company will work towards self-publishing both or one of the projects, which will also require additional funding.

We expect revenue to have increased year-on-year, but to remain at a relatively low level

We forecast Remedy's revenue to increase by 11% to 7.7 MEUR. In our forecast, the growth compared to the comparison period is driven in particular by royalty income (Q1’24e: 2.1 MEUR), which we expect to come in relatively nicely from Alan Wake Remastered, similar to the previous quarter. We expect development fees to have declined from the comparison period, when AW2 and Kestrel (then Vanguard), which was brought back to the drawing board, generated higher development fees. Resources have now been redirected to other projects, and we expect increasing development fees especially from the Max Payne project, which will go into production in Q2. Condor and Control 2 have also generated development fees, at least in January and February. Remedy subsequently acquired all rights to the Control game franchise from 505 Games, and is currently negotiating a potential new publishing partner while considering self-publishing the games.

H1 results still deep in the red ahead of AW2 royalties expected at year-end

We forecast Remedy's earnings development to reflect the ongoing investment phase in H1 before AW2 royalties start to flow in the second half of the year. Therefore, as in previous quarters, we expect Q1 EBIT to be significantly in the red (-7.9 MEUR). The full-year earnings development will be significantly impacted by the composition of the publishing agreement for Condor and Control 2 or the decision to self-publish the games.

Outlook clarified after final decisions on the Control projects

In its outlook, Remedy expects its revenue to increase from the previous year (2023: 33.9 MEUR) and EBIT (2023: -28.6 MEUR) to improve. Based on the very weak figures for 2023, the guidance does not yet provide much information value. For Condor and Control 2, the level of development fees for the current year and the coming years is uncertain due to the release agreements under negotiation or the decision to self-publish. The more risk Remedy wants to take on these projects, the less development fees will be generated. Correspondingly, this translates into higher royalty potential for Remedy. The company said it will clarify its outlook for 2024 once a decision has been made on the business model and potential arrangements for Control 2 and Condor. We will also revisit our estimates once the decisions on these games have been made. Our current forecast for this year is for a revenue of 50.4 MEUR (+49%) and an operating loss of -12.6 MEUR.

Remedy Entertainment is a game developer. Its operations are primarily focused on the development of action games, with a particular focus on 3D technology. Examples of games that the company has developed include several different versions of Alan Wake, Max Payne, and Control. Remedy also develops its own game engine and tooling technology that powers many of its games. The company was founded in 1995 and is headquartered in Espoo, Finland.

Read more on company page

Key Estimate Figures2024-03-20

202324e25e
Revenue33.950.459.5
growth-%-22.2 %48.6 %18.0 %
EBIT (adj.)-28.6-12.6-4.3
EBIT-% (adj.)-84.4 %-25.0 %-7.2 %
EPS (adj.)-1.68-0.72-0.25
Dividend0.000.000.00
Dividend %
P/E (adj.)neg.neg.neg.
EV/EBITDAneg.neg.173.7

Forum discussions

It seems quite clear that both characters are in the game and are related to the story. The open question is whether both are playable. It’s...
7 hours ago
by Jarnis
2
Unsurprisingly, some parts of the Internet are of the opinion that changing the main character is a mistake and the game is now ruined. From...
7 hours ago
by Flouride
5
Let’s make a separate poll to see if it works this way Control Resonant track sales by the end of 2026 Under 0.5M 0.5M - 0.99M 1M - 1.49M 1....
8 hours ago
by Henkka
2
Very much along the same lines. This increasing probability of momentum is further strengthened when examining the trend in the number of Nordnet...
9 hours ago
by Henkka
7
Control: It’s now just over a day since the first trailer for Control: Resonant was released. I took a closer look at the game’s reception, ...
10 hours ago
by Akee
31
Hello to the thread. I’ve also been a long-time Remedy bear, but I took a big position on this last Friday for under 16e. Not investment advice...
10 hours ago
by Umpi
12
Great trailer and the hype started nicely. Hopefully, the Remedyverse is hammered with a customizable sledgehammer into the black hole at the...
22 hours ago
by T4K1_
5
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.